BioSpace News Archive

Feb. 11, 2020 13:30 UTC Observational studies open to U.S. patients enrolled in Phase 3 VIOLET clinical trials who remain free of disease after 48 weeks DURHAM, N.C.--( BUSINESS WIRE )-- Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced it has initiated extension studies as part of its ongoing Phase 3 VIOLET clinical trials for oteseconazole (VT-1161). Mycovia is developing oteseconazole, an oral antifungal product candidate, for the treatment of Recurrent Vulvov

Selexis SA, a JSR Life Sciences Company, announced that Women In Bio has named Jessica Bosc, Selexis Director of Business Development and Licensing, as the organization’s President following a one-year term as President-Elect.

Feb. 11, 2020 13:30 UTC New York State Department of Health Approves Tests on GenFlex Platform, Enzo Biochem’s First Commercially Available High-Throughput Open Platform Approval of Gynecological Tests (CT/NG/TV) on GenFlex Platform Represents Sea-Change in Providing Cost-Effective Comprehensive Menu of Molecular Diagnostic Tests Genflex addresses the $450 million annualized global CT/NG/TV diagnostic market as well as the $1.3 billion Women’s Health market Further Valid

With promising results on its first rheumatological protein therapies, Dianomi is strategically expanding upon its core technology to deliver next-generation nucleic acid therapies

TauC3 Biologics Limited and Life Arc have been selected by the Tau2020 Global Conference Program Committee to present at Tau2020, being held in Washington, D.C., February 12-13, 2020.

DOYLESTOWN, Pa., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTCQB: KLFE) (“Kannalife” or the “Company”), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA) . The study was performed by Kannalife and the Lewis Katz School of Medicine at Temple Universi

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., welcomes Gail R. Wilensky, Ph.D., to the Council of Directors.

Reccently, the demand for medical devices such as protective clothing and masks soared, as did demand for devices including POCT testing reagents for the IVD industry, nucleic acid extraction devices, gene sequencing technology, medical imaging devices such as CT scanners; monitoring devices such as ECG monitors and blood gas analyzers; ICU products such as ventilators and ECMO; and medical robots.

Leadership Role Builds on FlowPlay’s Yearslong Fundraising Efforts to Support the American Cancer Society

Signatera test used for patient selection and monitoring to accelerate molecular proof of concept [11-February-2020] CAMBRIDGE , Mass. and SAN CARLOS, Calif. , Feb. 11, 2020 /PRNewswire/ -- Elicio Therapeutics , a next generation immuno-oncology company, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collabora